Skip to main content
. Author manuscript; available in PMC: 2013 Jun 20.
Published in final edited form as: Arch Intern Med. 2012 May 28;172(10):761–769. doi: 10.1001/archinternmed.2011.2230

Figure 3. Pooled Risk Ratios, with 95% CI, by trial for clinical renal endpoints (doubling of serum creatinine and ESRD).

Figure 3

Footnote: Data on the incidence of doubling of serum creatinine from UKPDS 33 was reported in 3 year intervals. Due to the marked drop-off of patients with outcomes reported at 9 years and beyond, the data from the 6 year time-point (n= 3,045) was chosen for inclusion in the summary data above. There was no difference in the magnitude or direction of effect at 9 and 12 years. At 9 years (n= 2,172), 0.71% vs. 1.76% (RR 0.40, 95% CI 0.14–1.20), and at 12 years (n=1,054), 0.91% and 3.5% (RR 0.25, 95% CI 0.07–0.91)had doubling of serum creatinine in the intensive vs. conventional groups. At 15 years (n=170), 3.52% in the intensive group and 2.8% in the convention group had doubling of serum creatinine (RR 1.25, 95% 0.16–9.55). Data on the incidence of ESRD and Death from Renal Disease are reported from the end of the study period. Intensive therapy was stopped earlier than planned in ACCORD. Data on renal outcomes were reported at transition to standard therapy (median follow-up 3.5 years) and at study end (median follow-up 5 years). The incidence of outcomes was taken from study end for the main analyses. Utilization of data from transition did not change the results for doubling of serum creatinine (pooled RR 1.08, 95% CI 0.95–1.23, I2 = 19%) or ESRD (pooled RR 0.70, 95% CI 0.45–1.08, I2 = 45%).